[HTML][HTML] Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study
N Murakami, TJ Borges, TS Win, P Abarzua… - American Journal of …, 2023 - Elsevier
Face transplantation is a life-changing procedure for patients with severe composite facial
defects. However, it is hampered by high acute rejection rates due to the immunogenicity of
skin allograft and toxicity linked to high doses of immunosuppression. To reduce
immunosuppression-associated complications, we, for the first time in face transplant
recipients, used low-dose interleukin 2 (IL-2) therapy to expand regulatory T cells (Tregs) in
vivo and to enhance immune modulation, under close immunological monitoring of …
defects. However, it is hampered by high acute rejection rates due to the immunogenicity of
skin allograft and toxicity linked to high doses of immunosuppression. To reduce
immunosuppression-associated complications, we, for the first time in face transplant
recipients, used low-dose interleukin 2 (IL-2) therapy to expand regulatory T cells (Tregs) in
vivo and to enhance immune modulation, under close immunological monitoring of …